In childhood acute lymphoblastic leukemia (ALL), persistence of leukemic blasts during therapy is of crucial prognostic significance. In the present study, we address molecular and cell biologic features of blasts persisting after 1 week of induction glucocorticoid therapy. Genome-wide gene expression analysis of leukemic samples from precursor B-cell ALL patients (n ¼ 18) identified a set of genes differentially expressed in blasts at diagnosis day 0 (d0) and persisting on day 8 (d8). Expression changes indicate a shift towards mature B cells, inhibition of cell cycling and increased expression of adhesion (CD11b/ITGAM) and cytokine (CD119/IFNGR1) receptors. A direct comparison with normal B cells, which are largely therapy resistant, confirmed the differentiation shift at the mRNA (n ¼ 10) and protein (n ¼ 109) levels. Flow cytometric analysis in independent cohorts of patients confirmed both a decreased proliferative activity (n ¼ 13) and the upregulation of CD11b and CD119 (n ¼ 29) in d8 blasts. The differentiation shift and low proliferative activity in d8 blasts may account for the persistence of blasts during therapy and affect their sensitivity to further therapeutic treatment. CD11b and CD119 are potential specific markers for d8 blast persistence and detection of minimal residual disease, which warrant further investigation. Leukemia (2007) 21, 897-905.
Introduction
In the multicentric ALL-BFM (Berlin-Frankfurt-Mü nster) study, patients are uniformly treated during the first week of induction therapy. The regimen includes the glucocorticoid prednisone as the principal therapeutic agent, administered on days 1-7 (d1-7) and one dose of methotrexate (MTX), which is given intrathecally at day 1. Subsequently, patients receive L-asparaginase, vincristine and daunorubicin for induction therapy. 1 Treatment response, assessed cytomorphologically after a 7-day induction prephase ('day 8 prednisone response'), provides one of the basic parameters for further treatment stratification. Patients with a reduction in the peripheral blast count to less than 1000/ml (prednisone good responders) have a more favorable prognosis than patients whose peripheral blast counts remain above this limit (prednisone poor responders). 2, 3 Differential therapy response is supposed to reflect the glucocorticoid (GC) sensitivity of the blast cells; however, the molecular mechanisms of GC action in vivo are largely unknown. 4, 5 Microarray-based gene expression profiling has been used to identify prognosis-associated signatures in childhood acute lymphoblastic leukemia (ALL). [6] [7] [8] [9] [10] It has also led to a large set of genes, which are potentially involved in GC response. [11] [12] [13] [14] [15] Accordingly, the hypotheses generated to explain the cytotoxic activity of GC are explicitly diverse, reaching from the direct activation of the apoptotic machinery to indirect deregulations of cellular functions, such as nucleotide and protein synthesis, energy metabolism, pH state and redox homeostasis. 11, 12, 16 Most studies have focused on gene expression in experimental cell systems. So far, only the study of Schmidt et al. 17 addressed mechanisms of GC action in a clinical setting. The authors analyzed early expression changes after onset of the induction therapy in the context of the ALL-BFM protocol (6 and 24 h). As a result, a small number of novel candidate genes have been identified, which do not support multiple model-based hypotheses. 17 For leukemic cells persisting after 1 week of ALL-BFM induction therapy (d8 blasts), several surface antigens have been analyzed using immunophenotypic measurements. 18 To date, the molecular properties of d8 blasts have not been studied on a genome-wide scale.
In the present study, we have undertaken a comprehensive characterization of ALL blasts persisting during induction therapy. Analysis of genome-wide gene expression, protein expression and cell cycle revealed common molecular and cellular features of d8 cells, which offer new insights into the biology of blasts resistant to induction therapy in ALL.
Materials and methods

Patients and primary cell material
Leukemic samples from children with precursor B-cell ALL (PBC-ALL) at initial diagnosis (day 0 (d0) samples) and after 7 days of initial therapy (d8 samples) were investigated. All patients were enrolled in the multicenter ALL-BFM 2000 study and gave informed consent in accordance with the Helsinki protocol. The diagnosis of ALL was based on morphology as well as cytochemical and immunophenotypic features. The criteria for the subclassification of PBC-ALL (pro-B, common and pre-B-ALL) were adopted from the guidelines proposed by the 'European Group for the Immunological Characterization of Leukemias'. 19 Early in vivo prednisone response to initial therapy was measured by cytomorphological detection of leukemic blasts in the peripheral blood (PB) on day 8.
Patient samples were investigated prospectively. The samples for genome-wide gene expression (n ¼ 18) were collected from April 2003 to September 2005. The selection was based on the availability of sufficient biological material at day 8. The minimal number of cells required for microarray analysis was approximately 100 blast cells/ml (Figure 1 ). Individual clinical features of patients, including age, sex, PBC-ALL subgroup, white blood cell counts (WBC), DNA ploidy, molecular translocations and d8 therapy response are given in Figure 2 .
The samples for the analysis of cell cycle distribution (13 patients) and protein expression (21-109 patients) were acquired between June 2005 and October 2006. The detection limit of cell cycle analysis was approximately 10 blast cells/ml, whereas flow cytometric protein detection was possible for samples containing a total of 200-400 leukemic cells (0.2 blasts/ ml in a PB sample of 1-2 ml). Clinical features of these patients are summarized in Supplementary Information and Supplementary Table S1 .
Primary cell material was derived from PB, with three exceptions (patients 2, 4, 9), where gene expression profiling of the d0 samples was carried out using bone marrow (BM). In an independent series of matched samples collected at diagnosis from 10 PCB-ALL patients, no significant expression difference between BM and PB could be detected (Supplementary Information).
In addition, normal mature B cells from d0 and d8 PB cell samples were analyzed for gene expression (10 samples from five patients) and protein expression (109 patients).
Cell sorting and assessment of protein expression and cell cycle by flow cytometry Flow cytometric analysis was performed using FC500 flow analyzer (Beckman Coulter, Miami, FL, USA). Cell sorting was performed using the cell sorter FACSVantage (Becton Dickinson, San Jose, CA, USA). Data on sorting accuracy and sample purity are provided in Supplementary Information and Supplementary Figure S1 .
Protein expression was assessed using antibodies against the cell surface antigens CD10 (Dako, Glostrup, Denmark), CD11b, CD34, CD45 (Coulter/Immunotech, Miami, FL, USA), CD20 and IFNGR1 (Becton Dickinson Biosciences, San Jose, CA, USA). To evaluate expression of the intracellular TdT (Dako), leukemic cells were fixed and permeabilized using the fixationpermeabilization kit (Fix and Perm, Caltag Laboratories, Hamburg, Germany). Leukemic blasts were identified by appropriate combinations of CD19, CD10, CD20 and CD34 antibodies. Viable cells were gated using forward vs side scatter plots. Mean expression values were calculated for viable leukemic cells using lin-log method (Cytomics RXP software, Beckman Coulter) and corrected for background staining using negative nonleukemic sub-populations. Detailed data on the monoclonal antibody clones and conjugated fluorochromes are provided in Supplementary Information and Supplementary Table S2 .
In order to perform cell cycle analysis, blast sub-populations were isolated by flow sorting, thus allowing to avoid high background noise resulting from non-leukemic cells present in d8 cell samples. To investigate cell cycle distributions, cells were ethanol fixed and propidium iodide (PI) stained as described elsewhere. 20 Gene expression analysis by oligonucleotide microarrays and real-time PCR Isolated cells were lysed in an RLT buffer and total RNA was extracted using the RNeasy Micro Kit (Qiagen, Hilden, Germany). The integrity of the isolated RNA was assessed using an Agilent 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA) (Supplementary Information and Supplementary Figure S1 ).
For oligonucleotide microarray hybridization, each RNA sample was linearly amplified by two rounds of in vitro transcription and labeled with biotin using the MessageAmp aRNA Kit (Ambion, Austin, TX, USA) and biotin-11-CTP and -16-UTP (Perkin-Elmer, Boston, MA, USA). Biotin-labeled cRNA was hybridized to Affymetrix GeneChip HG U133A chips (Affymetrix, Santa Clara, CA, USA) as described previously. 21 Verification of the microarray data for selected genes was performed by real-time reverse transcription-PCR (Supplementary Information and Supplementary Figure S1 ).
Data analysis
Normalization of the raw data was carried out using the variance-stabilizing procedure of Huber et al. 22 It returns normalized probe intensities on an additive scale. Probes within probe sets were summarized by fitting the additive model of Irizarry et al. 23 using a median-polish procedure. Affymetrix control probe sets and probe sets related to hemoglobin were removed. Clustering of samples was performed using average linkage hierarchical clustering, based on Pearson's correlation coefficients calculated including all genes in the data set.
Differential gene expression between d8 and d0 samples was measured using the average of paired expression differences across patients. Statistical significance was assessed by calculating P-values based on 1000 random permutations of the class labels, and subsequently estimating false discovery rates (FDR) based on the distribution of these P-values, as described previously. 24, 25 Principal component analysis (PCA) combined with the Jonckheere-Terpstra test was applied to assess consistent expression changes between days 0 and 8 towards expression levels of normal B cells. For a comparison of the ALL blasts persisting under therapy P Rhein et al present data to previously published data on the Affymetrix GeneChip HGU95av2, the 'Best Match' method was applied to match probe sets as provided by Affymetrix. Detailed methodological information on data preprocessing and statistical analysis is provided in Supplementary Information.
Results
Unsupervised hierarchical clustering using all genes
Leukemic and normal B-cell samples collected at d8 and d0 were clustered including all genes in the data set. Figure 2 shows that expression profiles of normal B cells cluster together separated from leukemic cells. Within the leukemic samples, it is remarkable that d8 blasts do not tend to form a distinct group but cluster with the patient-matched d0 samples in almost all cases (with the exception of two patients, 10 and 12), thus indicating that d8 cells largely originate from the bulk of leukemic cells at diagnosis. With regard to the clinical data, there is no grouping according to age, gender, WBC, whereas TEL/AML1-positive cases seem to cluster together. Prednisone good and poor responders do not form distinct clusters. However, one cluster is enriched by poor responders (second cluster from the top, Figure 2 ).
Differential gene expression between d0 and d8 blasts (d8/d0 gene set) Table S3 ). These genes were annotated using the gene ontology database. The majority of genes were assigned to the functional groups cell cycle regulation (47), metabolism (216), cell communication and stress response (104) and apoptosis (20) . In addition, some genes (14) were manually annotated with known functions in B-cell differentiation and development. Table 1 shows a subset of the d8/d0 gene set consisting of the top 20 representatives of each functional group. Cell-cycle-related genes comprise 10% of the genes in the list (47 of 457) ( Table 1 and Supplementary Table S1 ), including cyclins (CCNB2, CCND3, CCNG1), checkpoint kinases (CHEK1, BUB1B), cyclin-dependent kinases (CDK4, CDC2) and phosphatases (CDC25A). Together with decreased expression levels of genes involved in DNA replication (TOP2A, PCNA, RRM2, RFC4) and multiple effectors of mitosis execution (e.g. ZWINT, KNSL7, KIF11), these changes suggest an inhibition of cell cycle progression in blast cells persisting during therapy. The metabolism-related set comprised 47% of the list. The majority of them encode for effector enzymes, whose decreased expression at d8 suggests an impairment of metabolic activity in d8 blasts.
With regard to B-cell-specific genes, we observed a high number of genes encoding for known markers and key regulators of B-cell development (Table 1) . These include the progenitor markers CD10, CD34 and DNTT (TdT), whose decreased expression at mRNA and protein levels is a hallmark of the late stages of normal B-cell development. 26, 27 Consistently, we found an upregulation at d8 of the mature B-cell antigens CD20 and CD45. The key components of the pre-B-cell receptor (pre-BCR), the surrogate light chains VPREB1 and 2, and of BLNK (SLP65), the central molecule of the BCR proximal signaling complex 28 are downregulated at d8. LAT2 (LAB/ WBSCR5) cooperates with BLNK and provides a linkage Table 1 The set of genes differentially expressed at d8 and d0 (d8/d0 gene set) 29 This suggests a later stage of B-cell development and impaired pre-BCR signaling in the therapy persisting blasts.
ID
Most of the B-cell-related genes in the list are functionally involved in cell communication and stress response (Table 1) . This category comprises also genes that have not been reported before in the context of ALL. In particular, the genes encoding for the surface receptors IFNGR1 and CD11b are expressed at higher levels in the blast cells at d8 of therapy.
Apoptosis-related genes include members of the inhibitor of apoptosis protein (IAP) family, BIRC3 (cIAP2) and BIRC5 (survivin). Moreover, we found a downregulation of the gene encoding for the B-cell lymphoma 2 (BCL-2) protein, the prototypic member of the BCL-2 family involved in B-cell development and survival. 30 
Expression of d8/d0 genes in poor and good prednisone responders
The experimental approach of the study allowed investigation of samples from both good and poor prednisone responders (10 and eight patients, respectively; Figure 2 ). For the genes from the d8/d0 set, we calculated mean good/poor ratios of expression and analyzed their statistical significance at d0 and d8. Whereas expression differences between these groups at d0 were statistically not significant (data not shown), expression of more than 50% of the genes (272 probe sets) were found to be significantly different in poor vs good responders at day 8 (FDRo0.05). A comparison of the good/poor ratios with the d8/ d0 ratios for individual genes (Table 1 and Supplementary Table  S3) shows that genes, whose mean expression level has been decreased at d8, reveal lower expression levels in good responders than in poor responders and vice versa. In other words, the d8/d0 changes in good responders have been more pronounced than in poor responders, and as a result, a high number of genes become differentially expressed in good vs poor responder groups. In particular, the genes involved in metabolism (149 of 264 genes) and cell cycle (20/50) were expressed at a low level in blasts from good responders, indicating that the inhibition of proliferative and metabolic activity is more pronounced in this patient group. With regard to potential survival mechanisms, we observe that the expression of the antiapoptotic BCL-2 is higher in poor than in good prednisone responders. This difference, which may account for differential therapy response, warrants further investigation.
In addition to the comparison poor vs good, we analyzed the gene expression data in the context of parameters that describe the clinical follow-up of ALL patients. Almost all patients (n ¼ 16) achieved complete remission by morphological criteria, and there was only one relapse event so far. By PCR-MRD criteria, the groups of MRD-positive and MRD-negative cases (cutoff level 10
À4
) comprised 12 and 6 (day 33 of induction therapy) and 10 and 8 (day 78) patients. Analysis of gene expression data using the global gene set and the d8/d0 gene set, however, did not reveal significant differences between these groups. This result is not unexpected, given that treatment protocol after the first week of induction therapy includes antileukemic agents, which have a principally different mode of action from GCs.
Comparison of leukemic blasts and normal B cells
The observed expression changes in d8 blasts, in particular the downregulation of CD34, CD10, DNTT and the upregulation of CD20 and CD45, suggest a higher similarity to resting mature B cells. To test this hypothesis, we profiled gene expression in normal mature B cells and compared it to gene expression in leukemic blasts at days 0 and 8. A principal component analysis of the 457 genes from the d8/d0 comparison was performed (Figure 3) . The PCA projection onto the first two principal components account for 53% of the data variance. In Figure 3 , d8 samples are positioned between d0 samples and normal B-cell samples. Statistical significance of this observation could be established using the Jonckheere-Terpstra test. For both principal components, the changes in d8 blasts towards mature B cells are statistically significant (Po0.0001). In the latter test, normal B cells obtained from both, d0 and d8 samples, have been combined in one group, because these samples clustered together in the hierachical cluster analysis (Figure 2) . Moreover, we performed the d0 vs d8 differential gene expression analysis for normal B cells using the global gene set or the d8/d0 gene set, and we did not find genes that were differentially expressed with FDRo0.05.
Performance of the d8/d0 gene set in MTX-treated cells
The ALL-BFM therapy protocol involves one dose of MTX applied intrathecally at the beginning of GC therapy. It cannot be excluded that a leakage of MTX might have an influence on the gene expression in blasts in the PB. To this end, we made use of the data from Cheok et al. 31 The authors profile gene expression (Affymetrix GeneChip HGU95Av2 microarray) before and 1 day after therapy with four different treatment regimens, which include high-dose MTX or low-dose MTX and mercaptopurine. In the low-dose MTX regimen, which best corresponds with the ALL-BFM protocol, only 2.3% (7/308) of the genes within the d8/d0 set change their expression in the same direction as at d8. This result, although indirectly, indicates that the observed d8/d0 gene changes can be largely attributed to GC action.
Protein expression and cell cycle of d8 blasts
Validation of the key differences between d8 and d0 blasts has been addressed in independent sets of patients (Figure 4a) . First, ALL blasts persisting under therapy P Rhein et al we evaluated ALL cases with d8 blast counts above 100/ml, that is, within the same blast count range as in the DNA microarray experiments (Figure 1 ). In these cases, significantly decreased d8 vs d0 expression levels of CD10, CD34, DNTT and increased levels of CD20 and CD45 have been found (Po0.05), thus validating mRNA expression changes at the protein level (data not shown). Moreover, evaluation of the whole prospective series of patients demonstrates that these expression differences are also valid within the whole range of blast counts at d8 (Figure 4a ). Figure 4a also shows expression of the antigens in normal B cells, thereby confirming the differentiation shift of d8 blasts towards normal mature B cells at protein level (Figure 4a) . In order to identify surface proteins that may serve as novel d8-associated markers, we analyzed expression of the surface receptors IFNGR1 and CD11b, which revealed increased mRNA levels at d8 ( Table 1) . Expression of these proteins at d8 increased by 3.0-and 4.6-fold, respectively (Figure 4a ). Expression of IFNGR1 and CD11b in normal B cells, as compared with leukemic cells at d8, was significantly lower (1.4-and 3.2-fold, respectively). With regard to underlying mechanisms, both an upregulation of expression and a selection of the cells, already present at diagnosis at low frequencies, may be responsible for the observed expression changes. However, as illustrated in Figure 4b , at least in some individual samples, an upregulation of expression can be clearly demonstrated.
Cell cycle analysis was performed on blast sub-populations isolated by flow sorting. Fluorescence signals from at least 1000 blasts/sample were acquired in order to facilitate reliable quantification of rare cycling cells within sub-populations with very low proliferative activity. By this approach, leukemic sub-populations from d8 and d0 samples of 13 patients were investigated for DNA content distribution. The mean proliferation rate (percentage of cells in S and G2/M phases) was significantly lower in the blast cells persisting during therapy than in the samples at diagnosis (5.1 vs 1.2, P ¼ 0.03; Figure 4c ).
Given the prospective nature of this study and the overall low proportion of poor prednisone responders in ALL-BFM studies (5.5% among PBC-ALL patients), 1 the flow cytometric analysis included almost exclusively prednisone good responders (Supplementary Table S1 ). It would also be of interest to validate gene expression differences that have been detected when comparing poor and good prednisone responders at mRNA level; however, this would require an investigation of a considerably higher total number of patients. With regard to the clinical follow-up parameters, there were no statistically significant protein expression differences for MRD-positive and -negative groups of patients (at days 33 and 78).
Discussion
In the present study, we focused on molecular and cell biologic features of blasts persisting after 1 week of induction therapy according to the ALL-BFM protocol. We first applied the DNA microarray technique, which allowed for the evaluation of genome-wide gene expression patterns during therapy in individual patients. This analysis indicated changes in d8 cells at the levels of cell cycling, B-cell differentiation and expression of several novel surface markers. The subsequent analysis using more sensitive flow cytometric techniques confirmed the key gene expression changes in independent cohorts of patients. The hierarchical cluster analysis using all genes has demonstrated that d8 blasts do not form a distinct group but cluster pairwise with their matched d0 samples in the majority of cases. This indicates that d8 cells originate rather from the bulk of leukemic cells at diagnosis than from a pre-existing, initially 'hidden' subclone with a different expression profile. Analysis of DNA microarray data on expression changes associated with the application of MTX 31 indicated that the gene expression changes observed at d8 are largely due to GC effects.
GCs have been shown to exert the antiproliferative effects in multiple experimental cell systems, including lymphoid tissue. This effect, however, has not been investigated in clinical settings of ALL therapy. Our gene expression and flow cytometric analysis of purified leukemic cells directly demonstrates impaired proliferative activity in cells persisting during GC therapy. This has clinical implications, as actively proliferating cells are believed to be the major target of the genotoxic drugs applied in ALL therapy. The low proliferative activity may confer an increased resistance to drugs like vincristine and daunorubicin, and favors the application of the protein synthesis inhibitor L-asparaginase, whose mode of action is presumably less cell cycle dependent. 32 The differentiation shift in d8 cells towards normal B cells is another common feature of d8 cells. Given that normal mature B cells are generally more resistant to anti-leukemic treatment than leukemic blasts, these expression changes could contribute to the persistence of blasts at d8. It would be of interest to investigate the impact of the proliferative activity and the differentiation state of the blasts at d8 on therapy response and clinical outcome of individual patients.
The observed expression changes in d8 blasts pointed to several cell surface molecules, whose expression has not been reported in PBC-ALL. CD11b (ITGAM, MAC-1) may act as a transmembrane signaling molecule, which mediates survival in differentiated U937 cells, 33 and as a complement binding protein with a potential cytotoxic function.
34 IFNGR1 (CD119), a pleiotropic factor with immunoregulatory and anti-tumor properties, is functionally linked to Jak-Stat signaling and, thereby, can regulate survival signaling and apoptosis. 35 Both surface receptors revealed upregulated expression in independent cohorts of patients at mRNA and protein levels in d8 blasts. These data point to CD11b and IFNGR1 as d8 blast-specific markers. Moreover, their functional activity warrants further investigation of d8 blasts.
From the genes with a well-established antiapoptotic function, only the caspase inhibitor cIAP2 (BIRC3) has an increased expression at d8. cIAP2 protein upregulation after GC treatment has been reported in several cell systems, 36, 37 but its impact on GC resistance is dependent on the cell context. 36 Given the high cell quantity demand of cIAP2 detection by immunoblotting, it could not be validated in d8 blasts on protein level. Recently, the development of small cell-permeable molecules able to inhibit the antiapoptotic activity of XIAP, another member of IAP family, was reported. 38 Development of a drug against cIAP2 will lead to a tool to functionally investigate the role of this antiapoptotic factor in ALL GC resistance.
Our study for the first time compares global gene expression in PBC-ALL at diagnosis and after 1 week of induction therapy. To our knowledge, there are two studies that compared global gene expression in PBC-ALL at diagnosis and relapse. Of the genes differentially expressed at relapse and diagnosis in the study of Bhojwani et al. 39 two genes, PTTG1 and DUSP6, were also present in our d8/d0 set. In the second study, 40 which was restricted to pre-B ALL cases, another two genes, GTBP1 and TYMS, have been differentially expressed at d8 and d0. Thus, the overlap of the expression changes in the comparisons d0 vs d8 and d0 vs relapse is rather limited; however, it should be noted that these studies, in contrast to the present work, have been performed within the Children's Oncology Group protocol. 39, 40 In conclusion, the comprehensive characterization of d8 ALL cells identified common molecular and cell biologic features that may contribute to cell persistence under therapy, affect their sensitivity to further therapeutic treatment and/or serve as novel d8 and minimal residual disease markers.
